信立泰表示，SAL0137若能研发成功并获批上市，将有望为更多患者提供新的用药选择，满足未被满足 的临床需求，并进一步丰富公司慢病领域的创新产品管线。 北京商报讯（记者 丁宁）12月19日晚间，信立泰（002294）发布公告称，公司收到国家药品监督管理 局核准签发的《临床试验批准通知书》，同意公司自主研发的创新小分子药物SAL0137片开展治疗脂蛋 白（a）增高的临床试验。 ...

脂蛋白(a)[lipoprotein(a),Lp(a)]水平升高是冠心病、缺血性脑卒中、外周血管疾病、冠状动脉钙化及钙化 性主动脉瓣狭窄等的独立危险因素。Lp(a)通过促动脉粥样硬化、促炎和促血栓形成等多种机制，增加 心血管疾病(Cardiovascular disease,CVD)风险。临床前研究显示，SAL0137具有治疗Lp(a)增高的潜力， 具有一定开发潜力。 信立泰（002294）(002294.SZ)公告，公司收到国家药品监督管理局核准签发的《临床试验批准通知 书》，同意公司自主研发的创新小分子药物SAL0137片(项目代码：SAL0137)开展治疗脂蛋白(a)增高的 临床试验。 ...

人民财讯12月19日电，信立泰（002294）12月19日公告，近日公司收到国家药监局核准签发的《临床试 验批准通知书》，同意公司自主研发的创新小分子药物SAL0137片开展治疗脂蛋白(a)增高的临床试验。 ...

信立泰公告，近日，公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主 研发的创新小分子药物SAL0137片（项目代码：SAL0137）开展治疗脂蛋白（a）增高的临床试验。 ...

信立泰公告，公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的 创新小分子药物SAL0137片（项目代码：SAL0137）开展治疗脂蛋白（a）增高的临床试验。脂蛋白 （a）水平升高是冠心病、缺血性脑卒中、外周血管疾病、冠状动脉钙化及钙化性主动脉瓣狭窄等的独 立危险因素。Lp(a)通过促动脉粥样硬化、促炎和促血栓形成等多种机制，增加心血管疾病 （Cardiovasculardisease,CVD）风险。临床前研究显示，SAL0137具有治疗Lp(a)增高的潜力，具有一定 开发潜力。 ...

Group 1: Company Announcements - Tianpu Co. announced that its stock will resume trading on October 16 after completing an investigation into unusual trading activity, with a significant price increase of 317.72% over 15 consecutive trading days [1] - Haiguang Information reported a third-quarter net profit of 760 million yuan, a year-on-year increase of 13.04%, driven by a 69.6% increase in revenue [1] - Tailing Microelectronics expects a net profit of approximately 140 million yuan for the first three quarters, a year-on-year increase of about 118%, supported by strong sales of new AI chips and other products [2] Group 2: Financial Performance - Guanghua Technology achieved a third-quarter net profit of 34.13 million yuan, a year-on-year increase of 962.19%, with total revenue of 762 million yuan, up 14.99% [3] - JiuZhou Pharmaceutical reported a third-quarter net profit growth of 42.3% [5] - HeSheng New Materials anticipates a net profit increase of 60% to 80% for the first three quarters [5] Group 3: Investment and Partnerships - China Ruilin plans to participate in establishing a mining fund with a total scale of 2 billion yuan, focusing on rare metals such as tungsten and rare earths [4] - Zhenyang Development signed a strategic cooperation framework agreement with Ningbo Graphene Innovation Center [7] - Liying Intelligent Manufacturing intends to increase investment in its subsidiary Vietnam Guanghong by 11.025 million USD [7]

Core Viewpoint - The company, Sinopharm, has received approval from the National Medical Products Administration for its clinical trial application of the innovative small molecule drug SAL0137, which is intended for the treatment of elevated lipoprotein (a) levels [1]. Group 1 - The company announced that it has received the acceptance notice for the clinical trial application of SAL0137 [1]. - SAL0137 is an oral small molecule drug developed by the company with independent intellectual property rights [1]. - The clinical trial application submitted by the company is specifically for the treatment of elevated lipoprotein (a) [1].

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial application of its innovative small molecule drug SAL0137, which is intended for the treatment of elevated lipoprotein (a) levels [1] Group 1 - The drug SAL0137 is a self-developed oral small molecule medication with independent intellectual property rights [1] - The application submitted by the company is specifically for clinical trials of SAL0137 targeting elevated lipoprotein (a) [1]

Core Viewpoint - The company, Xinlitai (002294.SZ), has received a notice of acceptance from the National Medical Products Administration for its clinical trial application of the innovative small molecule drug SAL0137, which is intended for the treatment of elevated lipoprotein(a) levels [1] Group 1 - The clinical trial application for SAL0137 has been officially accepted, marking a significant milestone for the company's research and development efforts [1] - SAL0137 is an oral small molecule drug developed by the company, which holds independent intellectual property rights for this product [1] - The application submitted by the company specifically targets the treatment of elevated lipoprotein(a), indicating a focus on addressing cardiovascular-related conditions [1]

Core Viewpoint - The company, Xinlitai (002294.SZ), has received an acceptance notice from the National Medical Products Administration for its clinical trial application of the innovative small molecule drug SAL0137, which is intended for the treatment of elevated lipoprotein(a) levels [1] Group 1 - The clinical trial application for SAL0137 has been accepted, indicating progress in the drug development process [1] - SAL0137 is a proprietary oral small molecule drug developed by the company [1] - The application specifically targets the treatment of elevated lipoprotein(a), a significant health concern [1]